Inventiva (IVA) Q1 2026 TU earnings summary

Executive summary

• Cash and cash equivalents totaled €75.0 million, with €121.5 million in short-term deposits as of March 31, 2026, reflecting planned spending on the lanifibranor program.

• No revenues were recognized for Q1 2026, consistent with Q1 2025, as the company remains in the clinical stage.

• Lanifibranor is being evaluated in the pivotal Phase 3 NATIV3 trial for MASH, with topline results expected in Q4 2026.

Financial highlights

• Cash and cash equivalents decreased from €99.3 million at year-end 2025 to €75.0 million at March 31, 2026.

• Short-term deposits declined from €131.6 million to €121.5 million over the same period.

• Net cash used was primarily for operating activities related to R&D and the lanifibranor program.

Outlook and guidance

• Current liquidity is expected to fund operations until mid-Q1 2027; full exercise of Tranche 3 warrants could extend runway to mid-Q3 2027.

• Next financial results publication scheduled for July 29, 2026, including H1 2026 revenues and cash.

• Topline results from the pivotal NATIV3 Phase 3 trial are anticipated in Q4 2026.